These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16337831)

  • 61. Recent developments in human cytomegalovirus diagnosis.
    Halwachs-Baumann G
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):427-39. PubMed ID: 17547507
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Human immune responses to major human cytomegalovirus glycoprotein complexes.
    Liu YN; Kari B; Gehrz RC
    J Virol; 1988 Mar; 62(3):1066-70. PubMed ID: 2828655
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection.
    Schleiss MR
    J Pediatr; 2007 Dec; 151(6):564-70. PubMed ID: 18035130
    [No Abstract]   [Full Text] [Related]  

  • 64. Diagnosis and monitoring of human cytomegalovirus infection in bone marrow transplant recipients by quantitative competitive PCR.
    Ziyaeyan M; Sabahi F; Alborzi A; Mahboudi F; Kazemnejad A; Ramzi M; Moravej A; Jaberi MM
    Exp Clin Transplant; 2006 Jun; 4(1):470-4. PubMed ID: 16827646
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections.
    Permar SR; Schleiss MR; Plotkin SA
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343580
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Live cytomegalovirus vaccination of healthy volunteers: eight-year follow-up studies.
    Stern H
    Birth Defects Orig Artic Ser; 1984; 20(1):263-9. PubMed ID: 6329366
    [No Abstract]   [Full Text] [Related]  

  • 67. DNA vaccines against cytomegalovirus: current progress.
    Temperton NJ
    Int J Antimicrob Agents; 2002 Mar; 19(3):169-72. PubMed ID: 11932137
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prospects for the clinical management of human cytomegalovirus infections.
    Farrar GH; Bull JR; Greenaway PJ
    Vaccine; 1986 Dec; 4(4):217-24. PubMed ID: 3026105
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.
    Zhang C; Buchanan H; Andrews W; Evans A; Pass RF
    J Clin Virol; 2006 Mar; 35(3):338-42. PubMed ID: 16388984
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Flow cytometric analysis of virus-specific T lymphocytes: practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation.
    Buxbaum S; Kraus FB; Hahn A; Beck O; Kabartas B; Doerr HW; Ludwig B
    J Immunol Methods; 2006 Apr; 311(1-2):164-73. PubMed ID: 16530782
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169.
    Neff BJ; Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1979 Jan; 160(1):32-7. PubMed ID: 217022
    [No Abstract]   [Full Text] [Related]  

  • 72. Progress in cytomegalovirus vaccine development.
    Schleiss M
    Herpes; 2005 Dec; 12(3):66-75. PubMed ID: 16393522
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rapid generation of CMV pp65-specific T cells for immunotherapy.
    Bao L; Sun Q; Lucas KG
    J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.
    Mersseman V; Böhm V; Holtappels R; Deegen P; Wolfrum U; Plachter B; Reyda S
    Med Microbiol Immunol; 2008 Jun; 197(2):97-107. PubMed ID: 18320219
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.
    Zandvliet ML; Falkenburg JH; Jedema I; Willemze R; Guchelaar HJ; Meij P
    J Immunother; 2009 Jun; 32(5):513-23. PubMed ID: 19609244
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The status of cytomegalovirus vaccine.
    Starr SE; Friedman HM; Plotkin SA
    Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adoptive T cell immunotherapy for cytomegalovirus.
    Peggs KS
    Expert Opin Biol Ther; 2009 Jun; 9(6):725-36. PubMed ID: 19456207
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Human cytomegalovirus in patients with systemic lupus erythematosus.
    Hrycek A; Kuśmierz D; Mazurek U; Wilczok T
    Autoimmunity; 2005 Nov; 38(7):487-91. PubMed ID: 16373253
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection.
    Struble EB; Murata H; Komatsu T; Scott D
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445434
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections.
    Itell HL; Kaur A; Deere JD; Barry PA; Permar SR
    Curr Opin Virol; 2017 Aug; 25():126-133. PubMed ID: 28888133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.